Physician profile
Brian S Dantzler
NPI 1861438699
$1,675.73
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $844 · 2020: $241 · 2021: $590.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $760.95 | 2019-2021 | |
| Glaxosmithkline, LLC. | $222.93 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $122.69 | 2021 | |
| Biocryst US Sales Co., LLC | $111.37 | 2021 | |
| Csl Behring | $107.16 | 2019-2021 | |
| Genzyme Corporation | $78.13 | 2019-2021 | |
| Pfizer INC. | $56.71 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $50.00 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.69 | 2019-2021 | |
| Alk-Abello, INC | $37.54 | 2019-2021 | |
| Pharming Healthcare, INC. | $29.62 | 2021 | |
| Optinose US, INC. | $21.02 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $15.83 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $12.09 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Dantzler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.